In 2008, interventional gastroenterologists Drs. Christopher Thompson and Marvin Ryou, began pre-clinical investigations with an interest in non-surgical approaches to treat metabolic disorders.  Their developments were guided by 4 principles: 

  1. Focus on lasting mechanisms of action to treat metabolic disease
  2. Avoid long-term implants  —give nothing for the GI tract to reject over time
  3. Minimize delivery tools and procedure complexity
  4. Create a same day, endosuite procedure —with no general anesthesia required 

With a seasoned team of academic and industry engineers, the group explored a range research directions, filed intellectual property and developed a number of ideas that are the foundation of the GI Windows technology today. 

Management 

Peter Lukin: Chief Operating Officer
Mr. Lukin has over 25 years’ experience in new product development, operations, and general management of interventional endoscopic instruments and glucose sensors.  He was most recently the VP of Operations for Beacon Endoscopic, which developed and marketed a platform of endoscopic ultrasound devices which was acquired by Covidien in late 2013.  Prior to that, Mr. Lukin was the Bariatric Franchise Leader for Davol Inc., a division of CR Bard.  In that capacity, Mr. Lukin developed the EndoCinch©, a pioneering endoluminal suturing device used for primary treatment of obesity and revision of existing bariatric procedures. Prior to that, he was responsible for over 15 commercial product launches of biliary, tissue acquisition, enteral feeding and hemostasis endoscopic technologies.

Annette Fagnant: Clinical and Regulatory Consultant 
Ms. Fagnant has served the medical device industry for more than 30 years in both a regulatory affairs and clinical research capacity. She has extensive experience in strategy development and achieving clinical and regulatory submission approvals for a wide range of medical device products including minimally-invasive/non-surgical therapeutic devices in the obesity and type 2 diabetes space. Ms. Fagnant has successfully taken several products from “first-in-man” clinical experience to full regulatory approval both domestically and in global markets.  Prior to consulting, Ms. Fagnant was employed by Bard/Davol for nearly 10 years serving as the regulatory/clinical leader at the divisional and corporate level. Past clients include Beacon Endoscopic Inc., Davol Inc./CR. Bard Inc., Boston Scientific Corporation, Guidant Corporation, AngioDynamics Inc., Covidien, Johnson & Johnson as well as start-up companies focusing in the obesity market.

Board of Directors

Dr. Fred Moll, Director 
Frederic H. Moll, M.D. is the co-founder and CEO of Auris Surgical Robotics. Prior to Auris, Dr. Moll co-Founded Hansen Medical and served as the company's Chief Executive Officer from 2002 - 2010. Previously, Dr. Moll Co-founded Intuitive Surgical Inc., a medical device company, and served as its first Chief Executive Officer and later, its Vice President and Medical Director. Dr. Moll Co-founded Origin Medsystems, Inc., a medical device company, which later became an operating company within Guidant Corporation, a medical device company, following its acquisition by Eli Lilly in 1992. Dr. Moll served as Medical Director of Guidant's Surgical Device Division until November 1995.

Peter Rogal, Co-Chairman
Mr. Rogal has over 30 years of experience in the high tech electronics industry as a sales and marketing executive, serial entrepreneur and business executive.   Currently, Mr. Rogal is currently the CEO of Gold Circuit Electronics Global Sales and Services LLC.  Mr. Rogal is also the founder and 100% shareholder of Brooktrout Ventures, a small to midsized angel investing and marketing firm focusing on the electronics industry.  Mr. Rogal served as Chairman of the Board for Beacon Endoscopic, a high growth venture backed medical device company which was acquired by Covidien in 2013.  Mr. Rogal received his BS in Economics and Political Science from Ithaca College.

Dr. Christopher Thompson, Co-Chairman 
Dr. Thompson received his MD degree from Pennsylvania State University College of Medicine and completed advanced Clinical and Research fellowships at Harvard Medical School.  Dr. Thompson is currently Associate Professor of Medicine at Harvard Medical School. He is the current Director of Therapeutic Endoscopy & PI of the Developmental Endoscopy Lab at the Brigham and Women’s Hospital, Harvard Medical School.  He is the co-founder of Beacon Endoscopic and GI Windows. Dr. Thompson is one of the seminal international thought leaders in the rapidly emerging new fields of Natural Orifice Transluminal Endoscopic Surgery (NOTES) and Bariatric Endoscopy.  Dr. Thompson is also a founding member of NOSCAR, which is an innovative SAGES/ASGE consortium setting the future guidelines and ingenuity supporting NOTES procedures.  Dr. Thompson is also currently managing the grant research with C.I.M.I.T focused on the development of less invasive medical technologies.  For the past 5 years, Dr. Thompson has functioned as a consultant and medical advisory board member for members of industry ranging from Fortune 500 companies, venture capital firms to entrepreneurial corporations.  Dr. Thompson has also worked with industry for advanced Endoscopy training of sales and marketing personnel.  Dr. Thompson has published over 70 articles and abstracts in peer reviewed journals and has delivered over 80 presentations at Domestic and International conferences.

Dr. Marvin Ryou, Director 
Dr. Ryou is currently Assistant Professor of Medicine at Harvard Medical School.  He received a Medical degree at Harvard Medical School and subsequently completed clinical training at Brigham & Women’s Hospital and Massachusetts General Hospital. He is currently on staff as advanced endoscopist at Brigham & Women’s Hospital.  Dr. Ryou has served as consultant to various medical device companies, including Covidien and Beacon Endoscopic, Inc.  Dr. Ryou has published over 40 articles and abstracts in peer reviewed journals. Along with Dr. Thompson, Dr. Ryou is a co-inventor of the GI Windows technology, has performed the bulk of the pre-clinical work of GI Windows, and is a co-founder of GI Windows.

Brian Tinkham, Director
Mr Tinkham was Co-Founder and Director of Beacon Endoscopic, acquired by Covidien in 2013.  Mr Tinkham led financing of capital and debt, in excess of $11M, for Beacon Endoscopic and also led the commercialization strategy of products from design to global market adoption. Past experience includes global management with Boston Scientific (BSX), Vice President of Sales & Marketing with Mauna Kea Technologies (MKEA) and currently Vice President, New Technologies, GIS at Covidien.   Mr Tinkham has attended executive management programs at Columbia University, Heidelberg University, and has earned his undergraduate degree from UMass with an MBA from Northeastern University.

 

Scientific Advisors

Chris Thompson, MD, MSc; (Founder), Director, Bariatric and Developmental Endoscopy, Brigham and Women’s Hospital

Marvin Ryou, MD; (Founder), Interventional Gastroenterology, Instructor Harvard Medical School

Laurent Biertho, MD; Clinical Professor of Surgery, Laval University

Donald Simonson, MD; M.P.H., Sc.D.; Division of Endocrinology, Diabetes and Hypertension, Brigham and Women’s Hospital

David Lautz, MD, FACS; Head of Bariatric Surgery, Emerson Hospital and Massachusetts General Hospital

Paul Akerman, MD; Assistant Clinical Professor, Brown Medical School